Angioplasty Balloons Market Analysis

Angioplasty Balloons Market Overview

Angioplasty Balloons Market size is anticipated to hold a value of USD 2.85 Billion by 2032 and is expected to register a CAGR of 4.9% during the assessment period of 2023 to 2032.

With increasing cases of artery diseases, balloon angioplasty has become the method of choice to treat patients suffering from coronary and peripheral artery diseases. Cardiac diseases are rising at an enormous rate, and this calls for precise treatment alternatives with high success rates. Each year cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

Market Influencer

The companies operating in the angioplasty balloons market are focused on developing high-quality products incorporating cutting edge technologies. Also, established players are investing in clinical trials for the differentiation of products. Such initiatives promise a massive level of growth in the market. In addition to that, the increasing trend of minimally invasive procedures for the treatment of peripheral and coronary artery ailments is set to boost the market growth over the forecast period.

Market Drivers

• Rise in the number of collaborations and tie-ups by prominent players. For instance, in February 2017, QT Vascular (Singapore) signed a definitive agreement with Medtronic for the worldwide distribution of its Chocolate percutaneous transluminal angioplasty (PTA) catheter for five years and automatically renewable for two additional one-year periods.

• Rise in the incidence rates of cardiac diseases in developing as well as developed countries

• Rise in clinical trial candidates can boost the growth rate of the market during the assessment period. For instance, in November 2018, Koninklijke Philips N.V. (Netherlands) commenced patient enrolment for its Stellarex ILLUMENATE below-the-knee (BTK) investigational device exemption (IDE) clinical trial in the US. This study will compare the safety and effectiveness of the Stellarex 0.014 drug-coated angioplasty balloon to percutaneous transluminal angioplasty (PTA) in critical limb ischemia (CLI) patients.

• Increasing technological advancements and incorporation of innovation in the industry

• High investment in research and development

• Growing awareness created by medical professionals and key players about the benefits of angioplasty balloons

Market Restraints

• Product Recalls. In June 2019, Cook recalled three models of a balloon catheter used for leg angioplasty procedures after receiving multiple complaints of balloons bursting below the device's rated burst pressure.

• Side-effects and complications can reduce the preference rate

Angioplasty Balloons Market Segmentation

Angioplasty Balloons Product Insights

• Normal Balloons: The wide usage and availability of normal balloons contribute to the largest market share of this segment. Also, the reasonable cost of these products coupled with the favorable regulatory approval procedures is set to be a major contributor to the segment growth.

• Cutting Balloons: With the cutting balloon, the increase in the vessel lumen diameter is obtained in a more controlled manner and with a lower balloon inflation pressure than conventional balloons. This controlled dilatation could reduce the extent of vessel wall injury and the incidence of restenosis. This segment has been gaining popularity due to its high benefits and as a result, an increased preference rate. Thus, such factors are expected to drive the segment growth.

• Drug-Eluting Balloons: This segment is anticipated to be the fastest-growing during the assessment period owing to the increasing strategic initiatives taken by prominent players in the market. For instance, in August 2018, B. Braun Melsungen AG announced that its drug-coated balloon ‘SeQuent Please’ for percutaneous transluminal coronary angioplasty showed positive results in the BASKET-SMALL 2 clinical trial.

• Scoring Balloons: The increasing use of scoring balloons acts as a major reason for the growth of this segment. Several prominent companies are involved in the manufacturing of scoring balloons for coronary artery For instance, Koninklijke Philips N.V. (Netherlands) manufactures AngioSculpt PTCA, a scoring balloon that significantly highlights the landscape for treating coronary artery disease.

Angioplasty Balloons Application Insights

• 
  Coronary Artery Disease: The coronary artery disease segment held the largest share in 2019 owing to the increasing rate of cardiac diseases across the globe. For instance, cardiovascular disease accounts for 45% of all deaths in Europe. Such high statistics push the treatment rate for coronary artery disease, resulting in the growth of the segment.

• 
  Peripheral Artery Disease: This segment is expected to be the fastest-growing during the forecast period. The increased occurrences of peripheral artery diseases in developing countries are likely to boost the growth of the market. Also, rising product launches by key players significantly contribute to the growth of the market. For instance, in October 2019, introduced two new balloons to its Stellarex 0.035” low-dose drug-coated balloon (DCB) portfolio. These balloons broaden physicians’ treatment options for peripheral artery disease patients with a high risk of restenosis.

Angioplasty Balloons End-User Insights

• Hospitals: Hospitals held the majority share in 2018 owing to the high success rates of coronary and peripheral angioplasty procedures carried out in a hospital. On average, 200,000 cardiac arrests occur each year in hospitals in the US. Such strong statistics promises the growth of this segment in the coming years.

• 
  Cardiac Catheterization Laboratories: This segment is anticipated to be the fastest-growing during the forecast period owing to the rising cardiac intervention procedures conducted in these labs. The high uptake and adoption of patients and medical professionals towards the use of such labs boost the growth of this segment. For instance, more than one million diagnostic cardiac catheterizations (excluding percutaneous coronary intervention–only procedures) are performed each year in the nearly 2,000 cardiac catheterization laboratories in the US.

• Ambulatory Surgical Centers: The surging incidence rates of peripheral artery push for faster treatment access and alternatives. The reduced turnaround time that ambulatory surgical centers provide to the patients is driving the growth of this segment.

• Others: Others include academic organizations, and research firms, simulation centers.

Region Analysis

• Americas: Americas held the largest market share in 2019, owing to the presence of major players, such as Boston Scientific Corporation and Cardinal Health. Also, several companies are entering into tie-ups to expand their geographical footprints, leading to an increase in the market share of the Americas angioplasty balloons market.

• Europe: The European region holds the second largest share owing to a surging case of hospitalizations for techniques such as carotid artery angioplasty and cerebral angioplasty. Also, there are a substantial number of major players in the European countries who focus on strategic moves, including joint ventures, mergers, and acquisitions to strengthen their presence in the market space. For instance, in August 2017, Koninklijke Philips N.V. (Netherlands) completed the acquisition of Spectranetics Corporation, a US-based global leader in vascular intervention and lead management solutions.

• Asia-Pacific: The Asia-Pacific region is predicted to be the fastest-growing region in the global angioplasty balloons market. Vigorous marketing activities by the manufacturers are playing a substantial role in increasing the potential targets, thus increasing the market size in this region. For instance, in August 2018, Medtronic (Ireland) started selling its IN.PACT Admiral drug-coated balloon (DCB) in Japan, thus increasing the Japan angioplasty balloons market share in the APAC region.

• Middle East & Africa: This region holds the least share but is likely to rise in the near future due to the inclination of prominent companies to untapped regions.

Key Players

• 
  Abbott (US)


• Braun Melsungen AG (Germany)


• R. Bard (BD) (US)


• Biotronik SE & Co. KG (Germany)


• Boston Scientific Corporation (US)


• Cordis (Cardinal Health) (US)


• Cook (US)


• Koninklijke Philips N.V. (Netherlands)


• Medtronic (Ireland)


• Terumo Medical Corporation (Japan)


• Endocor (Germany)